Axiota Animal Health, a Colorado-based global animal health company, announced this week a development and licensing agreement with Resilient Biotics, a North Carolina-based company pioneering novel microbiome-based animal products using multi-level approaches. -advanced omics, data science and in vitro screening technologies. Agreement grants Axiota exclusive worldwide rights to Resilient Biotics’ proprietary treatment for bovine respiratory disease (BRD) and additional collaboration with Resilient Biotics for additional product development and commercialization of important indications in the global livestock market . As part of the collaboration, Axiota has also made a direct investment in Resilient Biotics and plans a multi-year effort to develop a portfolio of new products.
Jon Lowe, CEO of Axiota, said this agreement reaffirms Axiota’s commitment to pursuing innovative solutions for its customers.
“Combining Resilient Biotics’ advanced microbiome genomics and data science with Axiota’s proven ability to develop and commercialize novel microbes will allow us to better serve the bovine industry with best-in-class products that meet to the health, well-being, environment and environment of our customers. economic goals. The innovation resulting from this collaboration will integrate seamlessly with our existing portfolio of LactiproNXT, LactiproFLX and Multimin 90 and enhance the value we bring to our customers.
Resilient Biotics’ BRD technology gained industry notoriety when it was announced as the winner of the 2021 Beef Alliance Startup Challenge Award.
Chris Belnap, Ph.D., co-founder and CEO of Resilient Biotics, said, “We have built a discovery platform entirely focused on using healthy microbial strains to combat harmful pathogens in farm animals. , especially those that cause respiratory diseases. BRD technology has the potential to replace the routine use of antibiotics in cattle and could fill a critical gap in preventive care to combat this costly disease.Using scientific advances to understand the complexity of interactions between animal and the microbiome offers a new path for exciting and innovative products in animal health. »
Belnap added: “We believe this agreement will accelerate the development of our product for the treatment of BRD. We are both optimistic and eager to enter into this strategic collaboration with Axiota as they extend their commitment to a new premium cattle product. Axiota’s MS Biotec Microbial Technology Center has been a leader in the development of new microbes for animal health for over a decade, and they have significant market reach with deep expertise in cattle.
William “Bill” Weldon, Ph.D., former CEO and current Technology and Innovation Advisor to Axiota, said, “The synergy between these two companies results in world-class microbial discovery, product development and commercialization team focused on using the latest technologies to develop cattle products that solve some of the most important problems for cattle producers.Resilient Biotics’ discovery capabilities combined with expertise in stabilization, formulation and Axiota’s MS Biotec Microbial Technology Center manufacturing facilities create a unique and innovative microbial product development and commercialization platform, equipped to develop new products based on the latest microbiome science.